Up­start Oys­ter Point has big plans for dis­rupt­ing the oph­thal­mol­o­gy space, but you'll have to wait for the de­tails

Tech­ni­cal­ly, Oys­ter Point Phar­ma­ceu­ti­cals is com­ing out of stealth mode to­day with a $22 mil­lion A round from NEA and Ver­sant that will fi­nance a pair of mid-stage stud­ies for re­pur­posed drugs which have been in-li­censed for the launch. But the full sto­ry on the San Fran­cis­co-based biotech is go­ing to have to wait a bit be­fore the ex­ecs in­volved can ful­ly re­veal their plans.

Part of their plan, though, in­volves hir­ing staff.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER